Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2021932rdf:typepubmed:Citationlld:pubmed
pubmed-article:2021932lifeskim:mentionsumls-concept:C1516213lld:lifeskim
pubmed-article:2021932lifeskim:mentionsumls-concept:C0014264lld:lifeskim
pubmed-article:2021932lifeskim:mentionsumls-concept:C0315417lld:lifeskim
pubmed-article:2021932lifeskim:mentionsumls-concept:C0920321lld:lifeskim
pubmed-article:2021932lifeskim:mentionsumls-concept:C1521801lld:lifeskim
pubmed-article:2021932pubmed:issue10lld:pubmed
pubmed-article:2021932pubmed:dateCreated1991-6-3lld:pubmed
pubmed-article:2021932pubmed:abstractTextWe report a phase I study in cancer patients being treated with i.v. bolus injections of highly purified lipopolysaccharide (LPS) Salmonella abortus equi. Twenty-four patients with disseminated cancer received escalating doses of LPS at 2-week intervals. Dose escalation was performed in six dose levels treating 3-6 patients at each level. Dose levels 1 and 2 consisted of 0.15 and 0.3 ng/kg, respectively. Further dose escalation up to 5.0 ng/kg was enabled by pretreatment with ibuprofen, which attenuated the constitutional side effects of LPS. The maximum tolerated dose was 4.0 ng/kg with dose-limiting toxicity being World Health Organization grade III hepatic toxicity. Hematological changes included transient decreases in WBCs affecting granulocytes, monocytes, and lymphocytes in a marked different pattern. Endogenous cytokine release occurred in an LPS dose-dependent manner as measured by tumor necrosis factor-alpha, interleukin-6, and macrophage colony-stimulating factor serum levels. Moderate antitumor activity in colorectal cancer was observed in the case of 2 patients. Phase II trials of LPS are currently in progress.lld:pubmed
pubmed-article:2021932pubmed:languageenglld:pubmed
pubmed-article:2021932pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2021932pubmed:citationSubsetIMlld:pubmed
pubmed-article:2021932pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2021932pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2021932pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2021932pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2021932pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2021932pubmed:statusMEDLINElld:pubmed
pubmed-article:2021932pubmed:monthMaylld:pubmed
pubmed-article:2021932pubmed:issn0008-5472lld:pubmed
pubmed-article:2021932pubmed:authorpubmed-author:GalanosCClld:pubmed
pubmed-article:2021932pubmed:authorpubmed-author:EngelhardtRRlld:pubmed
pubmed-article:2021932pubmed:authorpubmed-author:MackensenAAlld:pubmed
pubmed-article:2021932pubmed:issnTypePrintlld:pubmed
pubmed-article:2021932pubmed:day15lld:pubmed
pubmed-article:2021932pubmed:volume51lld:pubmed
pubmed-article:2021932pubmed:ownerNLMlld:pubmed
pubmed-article:2021932pubmed:authorsCompleteYlld:pubmed
pubmed-article:2021932pubmed:pagination2524-30lld:pubmed
pubmed-article:2021932pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2021932pubmed:meshHeadingpubmed-meshheading:2021932-...lld:pubmed
pubmed-article:2021932pubmed:meshHeadingpubmed-meshheading:2021932-...lld:pubmed
pubmed-article:2021932pubmed:meshHeadingpubmed-meshheading:2021932-...lld:pubmed
pubmed-article:2021932pubmed:meshHeadingpubmed-meshheading:2021932-...lld:pubmed
pubmed-article:2021932pubmed:meshHeadingpubmed-meshheading:2021932-...lld:pubmed
pubmed-article:2021932pubmed:meshHeadingpubmed-meshheading:2021932-...lld:pubmed
pubmed-article:2021932pubmed:meshHeadingpubmed-meshheading:2021932-...lld:pubmed
pubmed-article:2021932pubmed:meshHeadingpubmed-meshheading:2021932-...lld:pubmed
pubmed-article:2021932pubmed:meshHeadingpubmed-meshheading:2021932-...lld:pubmed
pubmed-article:2021932pubmed:meshHeadingpubmed-meshheading:2021932-...lld:pubmed
pubmed-article:2021932pubmed:meshHeadingpubmed-meshheading:2021932-...lld:pubmed
pubmed-article:2021932pubmed:meshHeadingpubmed-meshheading:2021932-...lld:pubmed
pubmed-article:2021932pubmed:meshHeadingpubmed-meshheading:2021932-...lld:pubmed
pubmed-article:2021932pubmed:meshHeadingpubmed-meshheading:2021932-...lld:pubmed
pubmed-article:2021932pubmed:meshHeadingpubmed-meshheading:2021932-...lld:pubmed
pubmed-article:2021932pubmed:meshHeadingpubmed-meshheading:2021932-...lld:pubmed
pubmed-article:2021932pubmed:year1991lld:pubmed
pubmed-article:2021932pubmed:articleTitlePhase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients.lld:pubmed
pubmed-article:2021932pubmed:affiliationMedizinische Klinik I, Albert-Ludwigs-Universität, Freiburg, Federal Republic of Germany.lld:pubmed
pubmed-article:2021932pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2021932pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2021932pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2021932lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2021932lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2021932lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2021932lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2021932lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2021932lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2021932lld:pubmed